DGAP-News

Fresenius Medical Care AG & Co. KGaA: reports strong operating figures and confirms guidance for full year 2014 - Seite 2

North America revenue for the second quarter of 2014 increased by 6% to
$2,521 million. Organic revenue growth was 4%. Dialysis services revenue
grew by 7% to $2,316 million with a same store treatment growth of 3.3%.
Dialysis product revenue decreased by 6% to $205 million.

International revenue increased by 6% to $1,297 million (+7% at constant
currency). Organic revenue growth was 5%. Dialysis services revenue
increased by 8% to $633 million (+12% at constant currency). Dialysis
product revenue increased by 3% to $664 million (+3% at constant currency).

Earnings

Operating income (EBIT) for the second quarter of 2014 increased by 2% to
$556 million compared to $544 million in the second quarter of 2013.
Operating income for North America increased by 3% in the second quarter of
2014 to $401 million compared to $391 million in the second quarter of
2013. In the International segment, operating income for the second quarter
of 2014 increased by 11% to $243 million compared to $218 million in the
second quarter of 2013.

Net interest expense for the second quarter of 2014 was $98 million,
compared to $103 million in the second quarter of 2013.

Income tax expense was $177 million for the second quarter of 2014 which
translates into an effective tax rate of 38.7%. This compares to income tax
expense of $144 million and a tax rate of 32.6% for the second quarter of
2013. The tax rate in the second quarter of 2014 was influenced by a
special tax impact which resulted in an expense of $18 million in the
second quarter of 2014. On an adjusted basis the tax rate for the second
quarter of 2014 was 34.8%. For the full year, the company expects a tax
rate of around 34%.

Net income attributable to shareholders of Fresenius Medical Care AG & Co.
KGaA for the second quarter of 2014 was $234 million, a decrease of 11%
compared to the corresponding number of $263 million for the second quarter
of 2013. On an adjusted basis net income attributable to shareholders of
Fresenius Medical Care AG & Co. KGaA for the second quarter of 2014 was
$252 million.

Basic earnings per share (EPS) for the second quarter of 2014 was $0.77, a
decrease of 10% compared to the corresponding number for the second quarter
of 2013. On an adjusted basis EPS for the second quarter of 2014 was $0.83.
The weighted average number of shares outstanding for the second quarter of
2014 was approximately 301.8 million shares, compared to 306.3 million
shares for the second quarter of 2013. The decrease in shares outstanding
resulted from last year's share buy-back program, partially offset by stock
option exercises in the past twelve months.